GSA Capital Partners LLP Grows Stock Position in Cardiff Oncology, Inc. (NASDAQ:CRDF)

GSA Capital Partners LLP raised its stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) by 432.7% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 186,650 shares of the company’s stock after acquiring an additional 151,613 shares during the period. GSA Capital Partners LLP’s holdings in Cardiff Oncology were worth $498,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently modified their holdings of CRDF. Assenagon Asset Management S.A. grew its position in shares of Cardiff Oncology by 380.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock valued at $2,699,000 after acquiring an additional 962,940 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Cardiff Oncology during the 2nd quarter valued at about $256,000. XTX Topco Ltd acquired a new stake in shares of Cardiff Oncology during the 2nd quarter valued at about $185,000. Renaissance Technologies LLC boosted its holdings in Cardiff Oncology by 82.9% in the 2nd quarter. Renaissance Technologies LLC now owns 157,490 shares of the company’s stock worth $350,000 after buying an additional 71,390 shares during the last quarter. Finally, Blair William & Co. IL boosted its holdings in Cardiff Oncology by 32.2% in the 2nd quarter. Blair William & Co. IL now owns 227,630 shares of the company’s stock worth $505,000 after buying an additional 55,450 shares during the last quarter. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. HC Wainwright lowered their price objective on Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Craig Hallum assumed coverage on Cardiff Oncology in a report on Friday, September 6th. They issued a “buy” rating and a $8.00 price objective on the stock.

Cardiff Oncology Price Performance

Shares of Cardiff Oncology stock opened at $2.62 on Wednesday. The stock has a market cap of $133.96 million, a P/E ratio of -2.79 and a beta of 1.93. The stock’s 50 day simple moving average is $2.83 and its 200-day simple moving average is $2.70. Cardiff Oncology, Inc. has a 1-year low of $1.12 and a 1-year high of $6.42.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.